Biomakers

If you require publicly documented security certifications (SOC 2 Type II, ISO 27001) prior to procurement

• Biomakers does not appear to publish these artifacts in accessible materials.

If you need transparent, self-serve pricing and standardized SaaS procurement motions

• Biomakers appears to be quote-based and program-based (sponsored testing) rather than a published tiered SaaS plan.

If your primary need is FDA-approved companion diagnostics with a long-established US payer/regulatory footprint

• Foundation Medicine and other established CGP providers may be better aligned depending on jurisdiction and indication.

If you need a product with extensive third-party software reviews

• Biomakers has limited presence on mainstream review platforms; buyers who depend on those signals may prefer more widely reviewed vendors.

Current limitations acknowledged by the vendor

• Not explicitly listed as “limitations” in surfaced materials.

Roadmap / features not yet available

• Not publicly documented.

Scale limitations

• Not documented; dataset and biobank scale are vendor-stated, but performance and throughput constraints are not discussed.

Security or compliance gaps (public documentation)

• Security certifications and enterprise security feature documentation are not publicly documented in accessible Biomakers sources.

API limitations or integration constraints

• No public integration or API documentation found.

Evidence limitations

• Lack of third-party product reviews and limited independent validation of scale and outcomes are key constraints in assessing product quality from public sources.

• The vendor states a large precision oncology presence in Latin America with high test volumes, a multi-country network, and a tumor biobank.
• A combined offering: genomic testing, clinical data, biobanking, and AI components.

• The company’s funding announcement and LATAM ecosystem coverage indicate investor interest and strategic direction, though these do not constitute independent verification of product quality.

• Public documentation of security and compliance, pricing transparency, and broader review presence in the market.

• De-identified sample reports
• Clinical validity and clinical utility evidence for offered assays
• Dataset documentation (data dictionary, missingness, harmonization approach)
• Biobank SOPs and chain-of-custody documentation
• Audit trails and governance processes

• Providers
  • Oncology practices and cancer centers across LATAM that require multi-gene testing workflows and report delivery (small clinics through enterprise hospital systems).
• Life sciences
  • Biopharma, biotech, and CROs seeking access to underrepresented genomic and clinical datasets and biospecimens; typically mid-market to enterprise R&D organizations.

• Oncology providers
• Clinical labs and diagnostics networks
• Biopharma and translational research

• Decision makers
  • Oncology program directors
  • Pathology and molecular lab leadership
  • Hospital innovation and research leadership
  • Biopharma RWE and translational medicine leads
• End users
  • Oncologists and care teams ordering and reviewing reports in PLUTON
  • Research informatics teams consuming curated datasets

• Access to advanced molecular testing in LATAM
• Fragmentation across testing, data, and biospecimens
• Need for improved representation of LATAM populations in global oncology R&D

• Strong fit
  • Institutions with meaningful oncology volumes and need for streamlined ordering and report workflows
  • Life science teams specifically needing LATAM representation and associated biospecimens
• Poor fit
  • Organizations requiring extensive public compliance attestations (SOC 2/ISO27001) before vendor engagement